Pacira BioSciences, Inc. — Director's Dealing 2011

Feb 2, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pacira Pharmaceuticals, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2011-02-02

Reporting Person: MPM BioVentures IV QP LP (10% Owner)
Reporting Person: MPM BioVentures IV GP LLC (10% Owner)
Reporting Person: MPM BioVentures IV LLC (10% Owner)
Reporting Person: MPM Asset Management Investors BV4 LLC (10% Owner)
Reporting Person: MPM BioVentures IV GmbH & Co. Beteiligungs KG (10% Owner)
Reporting Person: DOMBKOWSKI ASHLEY L (10% Owner)
Reporting Person: Vander Vort John (10% Owner)
Reporting Person: Scopa James Paul (10% Owner)
Reporting Person: St Peter Steven (10% Owner)
Reporting Person: Greene William (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	92980	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (Right to Buy)	$2.69	2014-01-21	Common Stock (37190)		Indirect
Warrant (Right to Buy)	$13.44	2017-12-29	Common Stock (41840)		Indirect
Series A Convertible Preferred Stock	$		Common Stock (1487680)		Indirect
Convertible Promissory Note	$		Common Stock (712567)		Indirect

Footnotes

F1: The shares are held as follows: 87,144 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 3,357 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 2,479 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. Vaughn M. Kailian, Ansbert Gadicke, Luke Evnin, Steven St. Peter, William Greene, James Paul Scopa, Ashley Dombkowski and John Vander Vort are the members of the general partner of BV IV QP, BV IV KG and members of AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.

F2: The warrants are held as follows: 34,857 by BV IV QP, 1,342 by BV IV KG and 991 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.

F3: The warrants are held as follows: 39,215 by BV IV QP, 1,510 by BV IV KG and 1,115 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.

F4: Each share of Series A Convertible Preferred Stock has no expiration date, is convertible at any time, in whole or in part, at the election of the holder, and will automatically convert upon the closing of the Issuer's initial public offering at a conversion ratio of 0.09298 shares of Common Stock for every 1 share of Series A Convertible Preferred Stock rounded down to the next whole number, for no additional consideration.

F5: The shares on a post-conversion basis are held as follows: 1,394,315 by BV IV QP, 53,717 by BV IV KG and 39,648 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.

F6: All principal and accrued interest on the Notes will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.

F7: The notes are held in the principal amount as follows: $8,200,858 by BV IV QP, $315,945 by BV IV KG and $233,196 by AM BV4. The principal and accrued interest of the notes is convertible into the following shares of Common Stock upon the closing of the Issuer's initial public offering: 667,848 by BV IV QP, 25,729 by BV IV KG and 18,990 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.